Caribou Biosciences Profit Margin

Caribou Biosciences (CRBU) currently reports a profit margin of -2016.03% as of March 2026. That compares with -1954.55% in the prior-year period — down 3.1% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Caribou Biosciences's profit margin history and peer comparisons.

Caribou Biosciences's profit margin decreased from -1954.55% to -2016.03% — a 3.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Caribou Biosciences's profit margin of -2016.03% is lower than the Healthcare sector average of 15.29%. That is roughly 13282.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Caribou Biosciences's current -2016.03% should be judged against Healthcare norms (sector average: 15.29%) and against CRBU's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2016.03%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Caribou Biosciences, and consider following CRBU for alerts when major investors trade the stock.